Stock Price
1.66
Daily Change
-0.60%
Yearly
-15.31%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 134.75 1.66 1.24% 31.09%
AstraZeneca 8,554.00 95.00 1.12% 9.96%
Curis 3.32 0.10 3.11% -66.77%
Cytokinetics 32.27 1.79 5.87% 59.36%
Epizyme 2.00 -0.01 -0.50% -83.04%
Five Prime Therapeutics 38.00 0 0% 1,339.39%
Gilead Sciences 68.00 -0.84 -1.22% 1.95%
Immunogen 5.57 0.17 3.15% -27.19%
Incyte Corp 74.31 -1.03 -1.37% -26.06%
Laboratory Of America 271.83 3.78 1.41% 22.46%
Novartis 78.14 0.92 1.19% -7.34%
Pfizer 53.14 0.60 1.14% 42.43%
Roche Holding 347.85 1.65 0.48% 7.71%
TG Therapeutics 15.22 0.46 3.10% -67.21%
Verastem 1.66 -0.01 -0.60% -15.31%
Ziopharm Oncology 0.95 0.07 8.31% -77.66%

Indexes Price Day Year
NASDAQ 13915 375.51 2.77% 4.85%
US2000 2038 34.06 1.70% -3.35%

Verastem
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.